Detalles de la búsqueda
1.
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.
Haematologica
; 106(4): 1120-1128, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32273478
2.
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Br J Haematol
; 184(5): 797-807, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30548583
3.
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
J Pathol
; 245(1): 61-73, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29464716
4.
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.
Am J Pathol
; 187(8): 1700-1716, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28627414
5.
A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.
Am J Hematol
; 93(7): 867-873, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658143
6.
Castleman Disease and Rosai-Dorfman Disease.
Semin Diagn Pathol
; 35(1): 44-53, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29217303
7.
In situ neoplasia in lymph node pathology.
Semin Diagn Pathol
; 35(1): 76-83, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29129357
8.
Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.
Br J Cancer
; 117(11): 1685-1688, 2017 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28949959
9.
Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.
Mod Pathol
; 30(1): 85-94, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27687004
10.
Pathological fracture from clinically occult breast cancer.
Lancet Oncol
; 22(3): e131, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33662289
11.
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Br J Haematol
; 173(2): 245-52, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26847165
12.
High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.
Ann Hematol
; 95(2): 253-62, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26573278
13.
Angioimmunoblastic T-cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression.
J Cutan Pathol
; 43(12): 1203-1210, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27596815
14.
NF-κB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas.
Nucleic Acids Res
; 42(17): 11025-39, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25200074
15.
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Br J Haematol
; 169(2): 188-98, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25521006
16.
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
Mod Pathol
; 28(10): 1297-314, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26248897
17.
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Mod Pathol
; 28(9): 1202-13, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26111978
18.
SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms.
Blood
; 121(4): 643-7, 2013 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-23165482
19.
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Blood
; 122(15): 2630-40, 2013 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23982177
20.
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Blood
; 121(22): 4529-40, 2013 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-23515929